PATENT

Docket No. 2026-4230US1

IN THE UNITED STATES PARENTAND TRADEMARK OFFICE

Applicant(s)

J. SCHLOM et al

Group Art Unit: 1644

Serial No.

09/155,590

Examiner: G.R. Ewoldt

Filed

September 30, 1998

For

MUTATED RAS PEPTIDES FOR GENERATION OF

CD8+ CYTOTOXIC T LYMPHOCYTES

Commissioner of Patents Washington, D.C. 20231

RESPONSE TO RESTRICTION AND SEQUENCE REQUIREMENTS AND AMENDMENT UNDER 37 C.F.R. §1.111

Sir:

This Amendment is submitted in response to the non-final Office Action dated May 23, 2000, requiring restriction/election of the subject matter of the claims of the application under 35 U.S.C. §121, and compliance with the Sequence Requirements under 37 C.F.R. §1.821-1.825. Also filed herewith is a substitute Sequence Listing, a statement under 37 C.F.R. §1.825(b), a Petition for an Extension of Time (one month) pursuant to 37 C.F.R. §1.136(a), and the fee pursuant to 37 C.F.R. §1.17(a)(1) to extend the time for response until July 23, 2000. Applicants respectfully request entry and consideration of the substitute Sequence Listing and following amendments in view of the accompanying remarks at the time of examination of the application.